Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week Treatment, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (300 and 600 µg Once Daily) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 µg Twice Daily) as an Active Control

NCT00393458 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00393458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00393458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week Treatment, Multicenter, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol (300 and 600 µg Once Daily) in Patients With Chronic Obstructive Pulmonary Disease, Using Formoterol (12 µg Twice Daily) as an Active Control
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2006
Completion date
July 31, 2008
Enrollment
1,732 (actual)
Sites
183

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease